Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

234
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
234
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

221
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
221
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

322
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
322
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stagnation in the decline of TB in Japan: introduction of the pre-entry TB screening programme.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Hip Abductors Strength and Endurance in Individuals with Recent and Long-Standing Patellofemoral Pain.

Journal of athletic training·2025
Same author

Effectiveness of smoking cessation intervention based on the ABC Approach in patients with TB.

Public health action·2024
Same author

Pre-migration TB screening-the first step is always the hardest.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

A cost-effectiveness study of tuberculosis and latent tuberculosis infection screening in prisons in Japan.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

The challenges of the Philippines' social health insurance programme in the era of Universal Health Coverage.

Public health action·2019

Related Experiment Video

Updated: Jun 25, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.0K

Ensuring continuous TB treatment across Asian borders.

A Ohkado1, S Lee1,2, A Yoshie1

  • 1Department of Epidemiology and Clinical Research, Centre for Japan Pre-Entry Tuberculosis Screening (JPETS) Quality Assessment, Research Institute of Tuberculosis (RIT), Japan Anti-Tuberculosis Association (JATA), Kiyose.

Public Health Action
|May 27, 2024
PubMed
Summary

Cross-border migration of patients with tuberculosis (TB) can interrupt treatment. A new referral process in Japan improved healthcare access and treatment success rates for migrating TB patients, exceeding 80%.

Keywords:
loss to follow-upmigrantsreferraltreatment outcometuberculosis patient care

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.1K

Related Experiment Videos

Last Updated: Jun 25, 2025

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA
10:41

A Tuberculosis Molecular Bacterial Load Assay TB-MBLA

Published on: April 30, 2020

14.0K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.1K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Migration Health

Background:

  • Cross-border migration during tuberculosis (TB) treatment poses a significant risk of treatment interruption.
  • Ensuring continuity of care for migrating TB patients is crucial for successful treatment outcomes and disease control.

Purpose of the Study:

  • To establish and evaluate a cross-border referral system for TB patients migrating from Japan.
  • To enhance healthcare access and improve treatment outcomes for foreign-born TB patients returning to their home countries.

Main Methods:

  • Prospective cohort study design.
  • Tracking foreign-born TB patients who returned to their home countries during treatment.
  • Assessing access to healthcare facilities and treatment completion rates post-referral.

Main Results:

  • 135 foreign-born TB patients were enrolled; 112 (83.0%) accessed healthcare facilities in their home countries.
  • 87 out of 102 (85.3%) eligible patients completed their TB treatment.
  • Confirmed access to healthcare was significantly associated with treatment success (P < 0.001).

Conclusions:

  • The cross-border referral process facilitated healthcare access and treatment completion for over 80% of migrating TB patients from Japan.
  • Further improvements are needed to confirm treatment outcomes using official data.
  • The study highlights the effectiveness of structured referral systems in managing TB in mobile populations.